Precision matters when you are working with formulations where small volume changes equal significant dose changes
GLP-1R activation of neuroprotective pathways in neurons, microglia and astrocytes has also been reported: improvements in overall cognition, learning and motor function potentially associated with GLP-1RA administration in Alzheimers disease and Parkinsons disease may be mediated not only by their amyloid pathology-ameliorating properties (A, tau and -synuclein), but also the suppression of Ca 2+ deregulation and endoplasmic reticulum stress, anti-inflammatory activity, blockage of oxidative stress, mitochondrial dysfunction and apoptosis pathways, enhancements in the neuronal insulin sensitivity and energy metabolism, functional improvements in autophagy and mitophagy, elevated brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis, and neurogenesis 36
de Boer et al., 2018)
What to Expect When Beginning GLP-1 Peptide Therapy Treatment begins gradually
Cells 39, 6064
If you are ready to find out whether compounded semaglutide is right for you, visit our compounded semaglutide program page or call us at (817) 533-7676